Regeneron, Bayer Hit Back At Amgen In Eye-Med Patent Clash
Regeneron and Bayer have fought back against Amgen's bid to dismiss two major eye medicine patents at a London court, as they accused their opponent at the same time of planning...To view the full article, register now.
Already a subscriber? Click here to view full article